Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD
Published Web Location
https://doi.org/10.1038/nrneph.2017.60
Abstract
Key PointsCirculating alkaline phosphatase (ALP) is a robust and independent predictor of all-cause mortality in the general population and in patients with chronic kidney disease (CKD)Tissue-nonspecific ALP (TNALP) is the most abundant ALP isozyme in the body, comprising >90% of circulating ALP; functional differences between bone ALP (BALP) and liver TNALP are the result of post-translational glycosylationBALP promotes tissue mineralization by inactivating calcification inhibitors and by supplying phosphateLiver ALP and intestinal ALP (IALP) contribute to the immune response through dephosphorylation of circulating endotoxinsModulation of ALP is a potential novel treatment strategy that might reduce vascular calcification and improve cardiovascular outcomes in patients with CKD or diabetes mellitus type 2
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.